The Drug Repurposing journal aims to provide an interdisciplinary and cross-sectional overview of the various fields of research and applied sciences that work together to make successful drug repurposing projects a reality. High-throughput and high-content screening, in silico docking studies, pathway-based molecular pharmacology, bioinformatics, mining of peer-reviewed literature, patent documents, and side effect records, and design of drug repurposing trials are all part of this. We also welcome manuscripts that address strategic and ethical issues that are relevant in the broader context of drug repurposing, such as regulatory affairs, health technology assessment, and intellectual property. We especially welcome contributions that emphasize the specific integrative aspects of drug repurposing.

Drug Repurposing publishes high quality basic science, translational, and clinical research in the form of original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, technology reports, hypothesis articles, perspectives, and letters to the editor. The Journal publishes under the Creative Commons Attribution 4.0 (CC BY) license to ensure broad dissemination and participation.

Drug Repurposing e-ISSN: 2941-2528

Published by ScienceOpen GmbH, Berlin

Co-Editor-in-Chief

Hermann Mucke, H.M. Pharma Consultancy, Vienna, Austria

Harald H.H.W. Schmidt, MD, PhD, PharmD, Professor of Pharmacology, Chairman Department of Pharmacology and Personalised Medicine, Maastricht University

Editorial Board

Prof. Jörg Menche, University of Vienna

Robert Loewe, CEO, GENESURGE GMBH

Emre Guney, CTO & Head of Discovery and Data Science, STALICLA

Prof. Jan Baumbach, University of Hamburg

Markus List, PhD, Technical University of Munich

Thomas Krahn, Advisor, Invicol

Christoph Schröder, CEO, Sciomics GmbH

Prof. Federico Alvarez, Universidad Politécnica de Madrid

Jorika van Duijn-Wiersma, Managing Counsel, IPSIS PACTIS

Prof. Paolo Parini, Department of Laboratory Medicine, and Department of Medicine, Karolinska Institutet 

International and National Affairs Department, Karolinska University Hospital

Prof. Joseph Loscalzo, Physician-in-Chief Emeritus, Brigham and Women’s Hospital

Samuel A. Levine Professor of Medicine, Hersey Distinguished Professor of the Theory and Practice of Physic

Harvard Medical School, Boston, Massachusetts, USA

Martin Coenen, Head of Phase I-Unit, University Hospital Bonn

Prof. Dr. Manuela Joore, Head Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA) - Maastricht University Medical Centre +

Care and Public Health Research Institute (CAPHRI) - Maastricht University, The Netherlands

Liesbeth Ceelen, CEO, BioLizard

Prof. Ana Sofia Carvalho, Faculty of Medicine and Biomedical Sciences

Javad Nazarian, Group Lead, UZH

Christian Dr. Franken, CEO, DIHESYS

Dr. Bart Gips, Scientific Director, Machine2Learn BV

Frank Ruwe, 3D-PharmXchange

Prof. Romana Netea-Maier, Radboudumc Nijmegen The Netherlands

Prof. Jennifer Martin, The University of Newcastle Australia

Associate Prof. Chu Jang Hann, National University of Singapore

Submission of Manuscripts

All manuscripts must be submitted online through the "Submit a manuscript" button on this website. First time users will have to register at this site and will need an ORCID ID. Registration is free but mandatory. Registered authors can keep track of their articles after logging into the site. If you experience any problems, please contact info@scienceopen.com.
A manuscript will be reviewed for possible publication with the understanding that it is being submitted to Drug Repurposing alone at that point in time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. Manuscripts that have been previously posted as preprints in DrugRxiv, BioRxiv, MedRxiv, arXiv and related preprint repositories will be considered for publication. The journal expects that authors would authorize one of them to correspond with the journal for all matters related to the manuscript. All manuscripts received are duly acknowledged. On submission, editors review all submitted manuscripts initially for suitability. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding with formal peer-review.
Manuscripts that have met basic requirements and are within the scope of Drug Repurposing will be sent to two or more expert reviewers for evaluation. Manuscripts may be returned to the authors for major or minor revision after a first round of peer review.
Manuscripts finally accepted for publication are copy edited for grammar, punctuation, print style, and format and are tagged in XML mark-up language. Page proofs are sent to the corresponding author as PDF for review and approval. The corresponding author is expected to return the corrected proofs within 5-7 working days. Articles will be finally published with a Crossref Digital Object Identifier (DOI) as part of the permanent scientific record. Articles may only be removed through a formal retraction.

Authorship Criteria

Authorship credit should be based only on substantial contributions to each of the three components mentioned below: 

1. Concept and design of study or acquisition of data or analysis and interpretation of data;
2. Drafting the article or revising it critically for important intellectual content; and
3. Final approval of the version to be published.

Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript.

Conflicts of Interest/ Competing Interests

All authors of must disclose any and all conflicts of interest they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript.

Manuscript requirements

Manuscripts may be written in any standard program including Word and LaTeX. You can find a LaTeX template on Overleaf here: XXX. Authors will upload a pdf for peer review. Upon submission of revised manuscripts authors will also be requested to describe the changes made in the Revision Notes section and to submit a pdf version with tracked changes. Only after final acceptance of a manuscript will the author be requested to submit Word or LaTeX files for typesetting.

There are no strict formatting requirements, but all manuscripts should follow the basic structure for reporting scientific research below. The manuscript should be submitted as a pdf file:

Structure

The manuscript should include: Title page (title, authors, affiliations, contact, abstract, keywords (up to 10), conflict of interest statement), acknowledgments (Funder); Main text (introduction, materials and methods, results, discussion, figures with captions, tables with captions), References.

There are no word limits for submissions but manuscripts should be concise and well-written.

Title Page This page should include

1. Article title
2. Type of manuscript (original article, case report, review article, Letter to editor, etc.) title of the manuscript, names and affiliations of all authors/ contributors.
3. Authors. The names and affiliations of all authors as well as the name, address, e-mail of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs.
4. Author contributions. A description of work done by each author.
5. Conflicts of Interest of each author/ contributor. A statement of financial or other relationships that might lead to a conflict of interest.
6. Data availability statement
7. Code availability statement
8. Acknowledgements, if any. One or more statements should specify 1) contributions that need acknowledging but do not justify authorship, such as general support by a departmental chair; 2) acknowledgments of technical help; and 3) acknowledgments of financial and material support, which should specify the nature of the support. This should be included in the title page of the manuscript and not in the main article file.
9. Registration number in case of a clinical trial and where it is registered (name of the registry and its URL)

Methods section

Describe your experiment in as much detail as required for another researcher to reproduce your results. Use RRIDs (https://www.rrids.org/) to identify your research resources such as strains of organisms or antibodies. If a brand name is cited, supply the manufacturer's name and address (city and state/country).Follow all best practice reporting standards (e.g. the NIH, MDAR, and ARRIVE). If AI or machine learning was used provide an AIMe registry link (https://aime-registry.org). All submissions will undergo a scientific rigor check performed by SciScore( https://www.sciscore.com/) that analyses the methods section for compliance.

Use standardized nomenclature for species-specific gene and protein names (see Genecards, MGI Nomenclature page, HUGO Gene Nomenclature Committee, or equivalent resources).

Data

Refer to the Drug Repurposing Data Policy. Whenever possible follow the follow the FAIR (findable, accessible, interoperable, and reusable) data principles. You are strongly encouraged make your materials, data, protocols, code and scripts, available to readers in a public repository upon publication with exceptions for legal, ethical or logistical reasons. If you do not have requirements or support to publish data in an institutional or subject specific repository, search the DataCite Repository Finder  for appropriate repositories.Whenever possible data should be cited in the references section following the guidelines of the Joint Declaration of Data Citation Principles.

Tables

• Tables should be black and white/greyscale only and formatted as simply as possible for best accessibility. See some guidelines here: https://www.w3.org/WAI/tutorials/tables/
• Tables should be self-explanatory and should not duplicate textual material.
• Number tables consecutively in the order of their first citation in the text and supply a brief title for each.
• Place explanatory matter in footnotes, not in the heading.
• Explain in footnotes all non-standard abbreviations that are used in each table.

Figures

• Figures should be numbered consecutively according to the order in which they have been first cited in the text.
• To support the visually impaired, this journal includes Alt Text (alternative text), a short piece of text tagged to your figure to describe for readers contents of the image. This text can be used by screen readers to make the object accessible to people that cannot read or see the object.  Add Alt Text using Microsoft Word tools or as a separate figure caption. Further information on Alt Text for images can be found here: https://www.w3.org/WAI/tutorials/images/.
• It is the responsibility of authors/ contributors to obtain permissions for reproducing any copyrighted material. A copy of the permission obtained must accompany the manuscript.
• High resolution images may be requested upon acceptance of the manuscript.

References

References should be complete with DOI numbers if possible. The Journal uses the “Vancouver” numbering style and same reference style as PLOS (for those working with Paperpile, Endnote or other reference management systems). Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases. Examples of the format are listed below.

Submission of a revised manuscript 

The revised version of the manuscript should be submitted online in a manner similar to that used for submission of the manuscript for the first time. When submitting a revised manuscript, contributors are requested to include a point by point response to the reviewer comments and describe the changes made. In addition, they are expected to mark the changes as underlined or colored text in the article and submit this “Tracked changes” version along with their revised manuscript.

Publication schedule

The journal publishes articles on its website immediately on acceptance and follows a continuous publishing schedule.

Articles will be published Open Access under the terms of the Creative Commons Attribution License (CC-BY 4.0 License) which permits use, distribution and reproduction in any medium, provided that the work is properly cited.

This journal Network Medicine is generously funded through the European Project REPO4EU and there are currently no fees or article processing charges (APCs) associated with publishing in the journal.

Data Policy

By publishing in the journal authors are required to make research data available to editors and reviewers, and to readers upon request. For some research data, deposition in repositories is required and this is encouraged for all research data. For some papers, the decision to publish will be affected by whether or not authors share their research data.

Required

• Data sharing via repositories for some research data
• Data availability statements
• Data sharing on request

Optional / Encouraged

• Data citation
• Data sharing via repositories for all research data
• Data Management Plans

Each manuscript submission will be undergo an automated check for scientific rigor performed by SciScore and will reviewed by a least two subject experts in a single-blind workflow. Manuscripts that have been previously posted as preprints may submit open reviews of the preprint for consideration by the editorial team. Reviewers have the option of posting their reviews publicly on the ScienceOpen platform after an  article has been published.

Ethics

All material presented must be acquired according to ethical standards and approved by legally appropriate ethical committee(s).

We encourage authors to be aware of standardised reporting guidelines when preparing their manuscripts:

• Case reports - CARE
• Diagnostic accuracy - STARD
• Observational studies - STROBE
• Randomized controlled trial - CONSORT
• Systematic reviews, meta-analyses - PRISMA

In all cases of publication ethics the journal will refer to the Committee on Publication Ethics (COPE) guidelines: https://publicationethics.org/

Reporting research that involves human subjects or data requires a declaration that the investigations were carried out following the rules of the Declaration of Helsinki (https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/). Approval from the institutional review board (IRB) or other appropriate ethics committee must be obtained before undertaking the research to confirm the study meets national and international guidelines. A statement including the project identification code, date of approval, and name of the ethics committee or institutional review board must be included as ‘Institutional Review Board Statement’ article. For example: "All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of XXX (Project identification code)." The privacy rights of human subjects must always be observed.

The manuscript should follow the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) according to those recommendations. The terms sex and gender should be used correctly. Additionally, when studies describe groups by race, ethnicity, gender, disability, disease, etc., explanation regarding why such categorization was needed should be clearly stated in the article.

Contact

For technical or editorial support contact:

ScienceOpen at info@scienceopen.com

Author Agreement

Open Access Publishing Agreement

By submitting my manuscript to the journal Network Medicine published by REPO4EU (hereafter the ‘Publisher’) and managed by ScienceOpen, I herewith grant permission to the Publisher to publish my article upon editorial acceptance under the following publishing agreement.

I hereby confirm that this is my original work and that

• I own sole copyright in this work
• And/or I have obtained permission from all other Authors to execute this Agreement on their behalf if necessary

And that the work

• Has never been published before.

I understand that in granting this consent I am granting to the Publisher the Rights to publish under a Creative Commons CC-BY 4.0 license the Contribution in the English language in digital form; moral rights will be retained by the original Author/s and copyright will be held by the Author.

I agree to this Publishing Agreement, consent to execution and delivery of the Publishing Agreement electronically and agree that confirming my consent electronically during the manuscript submission process with an electronic signature shall be given the same legal force as a handwritten signature.

Terms of Use

1. The Contribution will be made Open Access under the terms of the Creative Commons Attribution License (CC-BY 4.0 License) which permits use, distribution and reproduction in any medium, provided that the Contribution is properly cited.
2. The Journal (and Publisher) reserves the right to require changes to the Contribution as a condition of its acceptance. The Journal (and Publisher) reserves the right, notwithstanding acceptance, not to publish the Contribution if for any reason such publication would in the reasonable judgment of the Journal (and Publisher), result in legal liability or violation of journal ethical practices. If the Journal (or Publisher) decides not to publish the Contribution, the Author is free to submit the Contribution to any other journal from any other publisher.
3. As above, the final Contribution will be made Open Access under the terms of the CC-BY license. Reproduction, posting, transmission or other distribution or use of the final Contribution in whole or in part in any medium by the Author as permitted by this Agreement requires a citation to the Journal suitable in form and content as follows: (Title of Contribution, Author, Journal Title and Volume/lssue, Digital Object Identifier (DOI), Date). Links to the final published Contribution should be provided following the guidance below on best practice.

Retained Rights

The Author retains all proprietary rights in addition to copyright, such as patent rights in any process, procedure or article of manufacture described in the Contribution.

Author's Representations

The Author(s) certify that they have participated sufficiently in the intellectual content, conception and design of this work or the analysis and interpretation of the data (when applicable), as well as the writing of the manuscript, to take public responsibility for it and have agreed to have their name listed as a contributor. The Author(s) believe the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, with the exception of online posting as a preprint. If requested by the editors, the Author(s) will provide the data/information or will cooperate fully in obtaining and providing the data/information on which the manuscript is based, for examination by the editors or their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in a "Conflicts of Interest" statement in the manuscript. Sources of outside support of the project are named in the Acknowledgements section.

Use of Information

The Author(s) acknowledges that, during the term of this Agreement and thereafter (for as long as necessary), the Publisher and the Journal may process the Author’s personal data, including storing or transferring data outside of the country of the Contributor’s residence, in order to communicate with the Author(s) and that the Publisher has a legitimate interest in processing the Author(s)’ personal data. By entering into this Agreement, the Author(s) agree to the processing of personal data (and, where applicable, confirms that the Author has obtained the permission from all other authors to process their personal data). The Publisher and the Journal shall comply with all applicable laws, statutes and regulations relating to data protection and privacy and shall process such personal data.

The journal Drug Repurposing welcomes submissions for the inaugural 2024 volume. 

Submit your manuscript by April 15th 2024 by clicking here.